Inzolfi

Fingolimod, the active ingredient in Inzolfi, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as an oral formulation for oral use. It functions as a disease‑modifying therapy for multiple sclerosis, specifically targeting relapsing‑remitting and active disease forms in adult patients.

GNH USA supplies Inzolfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing, regulatory compliance, and reliable distribution across EU and other global markets. The company adheres to stringent Good Distribution Practice (GDP) standards and provides full traceability from production to end‑user.

Inzolfi is a sphingosine‑1‑phosphate receptor modulator used in the management of multiple sclerosis and related disease activity.

- Relapsing‑remitting multiple sclerosis: reduces relapse frequency and slows disability progression. - Active secondary progressive multiple sclerosis: delays disability progression. - Overall disease activity in multiple sclerosis: provides disease‑modifying effects to limit new lesion formation.

Fingolimod may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Nasopharyngitis: upper respiratory symptoms such as sore throat and congestion. - Diarrhea: loose stools that may be self‑limiting. - Elevated liver enzymes: mild transaminase increases detectable on lab testing. - Hypertension: new‑onset or worsening blood pressure. - Cough: non‑productive cough without infection.

Serious or Rare Side Effects: - Infections: opportunistic infections including herpes virus reactivation. - Cardiac arrhythmias: bradycardia or atrioventricular block, especially after first dose. - Macular edema: visual disturbances requiring ophthalmologic evaluation. - Severe liver injury: marked transaminase elevation or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal demyelinating disease.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential risks.

- Monitor lymphocyte count: check baseline and periodic levels to detect lymphopenia. - Assess liver function: perform baseline and regular liver enzyme tests. - Screen for infections: evaluate for active infections and vaccinate appropriately before treatment. - Evaluate cardiac status: obtain ECG and monitor heart rate during first dose. - Avoid use in patients with active infection: defer treatment until infection resolves. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Fingolimod can interact with other medicines, requiring careful management.

Major Interactions (Avoid):\n- Concomitant use with other immunosuppressants: may increase risk of severe infections. - Live vaccines: can cause vaccine‑derived infection due to immune suppression. - Drugs that prolong QT interval: may exacerbate cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood pressure‑lowering effects. - Antidiabetic medications: monitor glucose control as fingolimod can affect glycemia. - CYP3A4 inhibitors or inducers: may alter fingolimod plasma concentrations, requiring dose adjustment or close observation.